Vitamin D supplementation represents an important topic in the field of metabolic bone disease. Calcidiol, the 25-hydroxy-vitamin D [25(OH)D], is the form of vitamin D most recently introduced in clinical practice. Advantages of the use of calcidiol derive from the pharmacokinetic properties and are related to the possibility of use in patients with liver disease, obese patients, patients with intestinal malabsorption, secondary hyperparathyroidism associated with chronic kidney disease as well as to avoid any possible toxic effect when high doses are used. The ADDI-D study demonstrated the efficacy and safety of calcidiol at the daily dose of 20 or 40 μg and 125 μg/week. In particular, the daily dose of 40 μg can be suggested as an alternative in severely deficient patients, as it has demonstrated to ensure higher vitamin D levels, compared to the 20 μg/day and the weekly 125 μg dose. The last can be an option when issues with compliance to the supplementation are present.

Oral calcidiol is a good form of vitamin D supplementation / Biondi, Piergianni; Pepe, Jessica; Biamonte, Federica; Occhiuto, Marco; Parisi, Martina; Demofonti, Chiara; Baffa, Valeria; Minisola, Salvatore; Cipriani, Cristiana. - In: CLINICAL CASES IN MINERAL AND BONE METABOLISM. - ISSN 1724-8914. - 14:2(2017), p. 207-208. [10.11138/ccmbm/2017.14.1.207]

Oral calcidiol is a good form of vitamin D supplementation

Biondi, Piergianni
Writing – Original Draft Preparation
;
Pepe, Jessica
Writing – Review & Editing
;
Biamonte, Federica
Writing – Original Draft Preparation
;
OCCHIUTO, MARCO
Writing – Review & Editing
;
PARISI, MARTINA
Membro del Collaboration Group
;
Minisola, Salvatore
Writing – Review & Editing
;
Cipriani, Cristiana
Writing – Original Draft Preparation
2017

Abstract

Vitamin D supplementation represents an important topic in the field of metabolic bone disease. Calcidiol, the 25-hydroxy-vitamin D [25(OH)D], is the form of vitamin D most recently introduced in clinical practice. Advantages of the use of calcidiol derive from the pharmacokinetic properties and are related to the possibility of use in patients with liver disease, obese patients, patients with intestinal malabsorption, secondary hyperparathyroidism associated with chronic kidney disease as well as to avoid any possible toxic effect when high doses are used. The ADDI-D study demonstrated the efficacy and safety of calcidiol at the daily dose of 20 or 40 μg and 125 μg/week. In particular, the daily dose of 40 μg can be suggested as an alternative in severely deficient patients, as it has demonstrated to ensure higher vitamin D levels, compared to the 20 μg/day and the weekly 125 μg dose. The last can be an option when issues with compliance to the supplementation are present.
2017
calcidiol; hypovitaminosis D; supplementation; vitamin D
01 Pubblicazione su rivista::01a Articolo in rivista
Oral calcidiol is a good form of vitamin D supplementation / Biondi, Piergianni; Pepe, Jessica; Biamonte, Federica; Occhiuto, Marco; Parisi, Martina; Demofonti, Chiara; Baffa, Valeria; Minisola, Salvatore; Cipriani, Cristiana. - In: CLINICAL CASES IN MINERAL AND BONE METABOLISM. - ISSN 1724-8914. - 14:2(2017), p. 207-208. [10.11138/ccmbm/2017.14.1.207]
File allegati a questo prodotto
File Dimensione Formato  
Biondi_Oral calcidiol_2017.pdf

solo gestori archivio

Tipologia: Documento in Pre-print (manoscritto inviato all'editore, precedente alla peer review)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 42.38 kB
Formato Adobe PDF
42.38 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1085727
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 6
social impact